Stress-reducing Intervention in Urothelial Carcinoma - Trial NCT06269536
Access comprehensive clinical trial information for NCT06269536 through Pure Global AI's free database. This phase not specified trial is sponsored by Comenius University and is currently Recruiting. The study focuses on Bladder Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Comenius University
Timeline & Enrollment
N/A
Feb 15, 2024
Feb 15, 2029
Primary Outcome
Primary Objective: Inflammation,Primary Objective: Heart Rate Variability (HRV),Primary Objective: Quality of Life (QoL),Primary Objective: Working memory,Primary objective: Executive function,Primary objective: Salivary Cortisol Slopes,Primary objective: Sleep Quality
Summary
The aim of this interventional study is to test the heart-rate variability biofeedback
 intervention (HRV BI) in patients with muscle-infiltrating bladder carcinoma (MIBC) treated
 with chemotherapy based on cisplatin in neoadjuvant setting followed by local therapy
 (standard of care, SOC) compared to SOC alone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06269536
Non-Device Trial